Holen Sie sich die Stockscreener-App
41.92
1.23%
-0.52
Handel nachbörslich:
41.92
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$42.44
Offen:
$42.35
24-Stunden-Volumen:
1.09M
Relative Volume:
0.89
Marktkapitalisierung:
$2.46B
Einnahmen:
$238.11M
Nettoeinkommen (Verlust:
$-31.45M
KGV:
-66.18
EPS:
-0.6334
Netto-Cashflow:
$7.66M
1W Leistung:
-3.23%
1M Leistung:
-17.42%
6M Leistung:
+26.53%
1J Leistung:
+134.98%
1-Tages-Spanne:
$41.74
$43.09
1-Wochen-Bereich:
$41.74
$44.68
52-Wochen-Spanne:
$15.27
$52.91
Axogen Inc Stock (AXGN) Company Profile
Firmenname
Axogen Inc
Sektor
Branche
Telefon
(386) 462-6817
Adresse
13631 PROGRESS BLVD., ALACHUA, FL
Compare AXGN vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AXGN
Axogen Inc
|
41.92 | 2.55B | 238.11M | -31.45M | 7.66M | -0.6334 |
ABT
Abbott Laboratories
|
98.83 | 175.27B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
86.29 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
275.39 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.65 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.32 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Axogen Inc Stock (AXGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-19 | Eingeleitet | Wells Fargo | Overweight |
| 2025-12-01 | Eingeleitet | Mizuho | Outperform |
| 2025-03-17 | Eingeleitet | Lake Street | Buy |
| 2024-07-01 | Eingeleitet | Raymond James | Outperform |
| 2022-11-11 | Fortgesetzt | Jefferies | Buy |
| 2022-05-09 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2022-03-11 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Eingeleitet | Guggenheim | Buy |
| 2020-06-16 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2020-05-07 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2020-04-02 | Herabstufung | BTIG Research | Buy → Neutral |
| 2019-08-07 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2019-07-12 | Eingeleitet | Canaccord Genuity | Buy |
| 2018-03-02 | Bestätigt | Lake Street | Buy |
| 2018-01-05 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2017-11-30 | Eingeleitet | Jefferies | Buy |
| 2017-11-21 | Bestätigt | Lake Street | Buy |
| 2017-07-31 | Eingeleitet | Leerink Partners | Outperform |
| 2017-06-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-03-06 | Eingeleitet | ROTH Capital | Buy |
| 2016-11-22 | Hochstufung | Lake Street | Hold → Buy |
| 2016-11-07 | Bestätigt | Wedbush | Outperform |
| 2016-11-03 | Herabstufung | Lake Street | Buy → Hold |
| 2016-08-04 | Bestätigt | Wedbush | Outperform |
| 2014-05-14 | Eingeleitet | Dawson James | Buy |
| 2013-10-31 | Bestätigt | Ladenburg Thalmann | Buy |
Alle ansehen
Axogen Inc Aktie (AXGN) Neueste Nachrichten
Raymond James raises AxoGen stock price target on growth outlook By Investing.com - Investing.com Nigeria
AXGN Maintains Outperform Rating by Raymond James -- Price Targe - GuruFocus
Raymond James raises AxoGen stock price target on growth outlook - Investing.com
10 Health Care Stocks Whale Activity In Today’s Session - Benzinga
AxoGen (AXGN) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
AXGN | Axogen, Inc. Common Stock FinancialsRevenue Breakdown - Quiver Quantitative
Axogen Inc (AXGN) Shares Fall 3.0% -- GF Value Says Still Overva - GuruFocus
Axogen: Sales Sprint Ahead; Profitability Takes a Breather - Orthopedics This Week
Axogen, Inc.Common Stock (Nasdaq:AXGN) Stock Quote - The Chronicle-Journal
Axogen Stock Price Forecast. Should You Buy AXGN? - StockInvest.us
AxoGen, Inc. (AXGN) Stock Analysis: Healthcare Innovator With A 19% Potential Upside - DirectorsTalk Interviews
Axogen, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:AXGN) 2026-07-29 - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: AxoGen (AXGN) and Definium Therapeutics (DFTX) - The Globe and Mail
Axogen to acquire BioCircuit Technologies for $200 million - Indian Pharma Post
Lake Street Maintains AxoGen(AXGN.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Axogen to acquire BioCircuit Technologies - Medical Buyer
Axogen (NASDAQ: AXGN) Plans $200M Acquisition of BioCircuit Technologies Backed by Stock Offering - Kalkine Media
Axogen (NASDAQ: AXGN) Releases Updated Investor Presentation on September 10, 2026 - Kalkine Media
Axogen deepens nerve repair portfolio through $200m BioCircuit takeover - Yahoo Finance
Axogen announces pricing of public offering - medicalbuyer.co.in
Axogen prices $208.7 million stock offering at $42.50 per share By Investing.com - Investing.com Australia
Axogen Inc (AXGN) Shares Fall 11.5% -- What GF Score of 64 Tells Investors - GuruFocus
AXGN 424B FilingsAxogen Inc SEC 424B - Stock Titan
Axogen To Acquire BioCircuit Technologies For $200 Million To Add Sutureless Nerve Repair Platform - Pulse 2.0
Why Is Axogen Stock Tumbling Today?Axogen (NASDAQ:AXGN) - Benzinga
Axogen to buy BioCircuit Technologies for $200M - medtechdive.com
Axogen Announces $200 Million Acquisition of BioCircuit Technologies Alongside $42.50 Per Share Stock Offering - Kalkine Media
Axogen to acquire Biocircuit for $200M - BioWorld News
2 Medical-Device Stocks Lighting Up the Options Pits - schaeffersresearch.com
Axogen stock falls as $208.7M offering dilutes shareholders By Investing.com - Investing.com Australia
Form 8K Axogen Inc For: 10 September By Investing.com - Investing.com South Africa
Why is Axogen stock sliding today? By Investing.com - Investing.com Australia
Axogen stock falls as $208.7M offering dilutes shareholders - Investing.com India
Axogen Prices $208.7 Million Stock Offering to Fund BioCircuit Acquisition - citybiz
Axogen to Acquire BioCircuit Technologies in $200 Million Nerve Repair Deal - citybiz
Why is Axogen stock sliding today? - investing.com
Axogen acquires BioCircuit Technologies for $200 million - grafa.com
Axogen Announces Pricing Of $208.7 Million Public Offering Of Common Stock - TradingView
AxoGen to Acquire BioCircuit, Expanding Nerve Repair Portfolio - TipRanks
Axogen prices $208.7 million stock offering at $42.50 per share - investing.com
AXGN Looks 171.8% Overvalued on GF Value™ - GuruFocus
Axogen to acquire BioCircuit for $200M, adds nerve repair device - Investing.com Canada
Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock - manilatimes.net
Axogen Prices $208.7 Million Public Offering of Common Stock to Help Fund BioCircuit Acquisition - Quiver Quantitative
AXGN: Acquisition of a pioneering sutureless nerve repair device is expected to drive growth and innovation - TradingView
Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies - GlobeNewswire
Axogen, Inc. agreed to acquire BioCircuit Technologies, Inc. for approximately $200 million. - marketscreener.com
Understanding the Setup: (AXGN) and Scalable Risk - Stock Traders Daily
Axogen Director Tyndall Joseph A. Disposes of 3,500 Shares at $49.70 Each - Kalkine Media
Axogen (AXGN) Director Joseph Tyndall Sells 3,500 Shares - GuruFocus
Axogen Inc (AXGN) Shares Fall 3.2% -- What GF Score of 64 Tells Investors - GuruFocus
Finanzdaten der Axogen Inc-Aktie (AXGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.75%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):